Media Library

Lead-shielded canisters contain radioligand therapy doses.

A lead-shielded canister that contains radioligand therapy doses.

Chief Financial OfficerMember of the Executive Committee

Board member since 2026

This report covers information on nonfinancial matters deemed material and in scope of our reporting obligations under the Swiss Code of Obligations (SCO), as well as our due diligence and reporting obligations in relation to child labor under the SCO.​It includes our Human Rights Statement addressing specific jurisdictional requirements for disclosure on modern slavery, decent work, forced labor and child labor.​

The Annual Report 2025, filed with the SIX Swiss Exchange in Switzerland, provides a comprehensive overview of Novartis, including our company structure, corporate governance, operating and financial results, and compensation practices.

Chief Executive Officer since 2018

Novartis executives and dignitaries cut ribbon on Novartis RLT manufacturing facility in Carlsbad, California, USA (November 10, 2025).

Novartis executives and dignitaries at the ribbon cutting ceremony for the RLT manufacturing facility in Carlsbad, California, USA (November 10, 2025).

Exterior view of our state-of-the-art radioligand therapy (RLT) manufacturing facility in Carlsbad, California, United States.

Novartis executives and dignitaries at the groundbreaking ceremony of the US Flagship Manufacturing Hub in Durham, North Carolina, USA (December 11, 2025).

Vas Narasimhan, Novartis CEO, with Josh Stein, Governor of North Carolina, at the groundbreaking ceremony of the US Flagship Manufacturing Hub in Durham, North Carolina, USA (December 11, 2025).